[HTML][HTML] Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
AI Daud, RC DeConti, S Andrews, P Urbas… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
AI Daud, RC DeConti, S Andrews, P Urbas, AI Riker, VK Sondak, PN Munster, DM Sullivan…
Journal of clinical oncology, 2008•ncbi.nlm.nih.govPurpose Gene-based immunotherapy for cancer is limited by the lack of safe, efficient,
reproducible, and titratable delivery methods. Direct injection of DNA into tissue, although
safer than viral vectors, suffers from low gene transfer efficiency. In vivo electroporation, in
preclinical models, significantly enhances gene transfer efficiency while retaining the safety
advantages of plasmid DNA.
reproducible, and titratable delivery methods. Direct injection of DNA into tissue, although
safer than viral vectors, suffers from low gene transfer efficiency. In vivo electroporation, in
preclinical models, significantly enhances gene transfer efficiency while retaining the safety
advantages of plasmid DNA.
Abstract
Purpose
Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection of DNA into tissue, although safer than viral vectors, suffers from low gene transfer efficiency. In vivo electroporation, in preclinical models, significantly enhances gene transfer efficiency while retaining the safety advantages of plasmid DNA.
ncbi.nlm.nih.gov
